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acute kidney injury in the setting of preexisting chronic
kidney disease.
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We did not collect post-infusion serum creatinine, so we
are unable to comment on the occurrence of acute renal
failure. The time frame of the study is simply too short to
detect progression of renal injury. The benefits and risks of
iron use in nephrology need to be clarified further.
A larger, NIH-funded, randomized trial is under way to
examine the effects of iron administration in patients with
chronic kidney disease on GFR (glomerular filtration rate)
slopes.
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To the Editor: We read with interest the ‘Renal consult’ on
uremic pruritus by Keithi-Reddy et al.,1 but we believe that a
major point regarding this topic has not been considered by
the authors. An emerging and intriguing pathogenetic
hypothesis on pruritus suggests that it can be due to
peripheral nerve fiber damage associated with a central
sensitization, leading to a diminished threshold of perception
of itch. This hypothesis is similar to that proposed for
neuropathic pain, in which nerve fiber damage and central
‘windup’ phenomenon are thought to be major patho-
mechanisms. Ongoing studies are now trying to clarify the
neurophysiologic pathways shared by itch and neuropathic
pain. Gabapentin, a medication widely used for a spectrum
of neuropathic pain syndromes, has recently been added
to the therapeutic armamentarium of uremic pruritus. Our
experience2 and other published randomized trials3,4 have
demonstrated that gabapentin can be effective and safe for
uremic pruritus, and that it also ameliorates neuropathic
symptoms (that is, restless leg syndrome, diabetic neuro-
pathy, and insomnia) that often affect hemodialysis patients’
quality of life. On the basis of these considerations, we believe
that Keithi-Reddy et al. should have discussed this point
and included gabapentin among the therapeutic options for
uremic itch.
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In response to our article,1 Manenti et al.2 suggest a role
for gabapentin in the management of uremic pruritus.
They make a similar point in a recent article.3 Gabapentin
is structurally related to c-amino butyric acid (GABA).
However, gabapentin does not bind to GABAA or GABAB
receptors, and does not appear to influence synthesis or
uptake of GABA. High-affinity gabapentin-binding sites
have been located throughout the brain and correspond to
the presence of presynaptically located voltage-gated
calcium channels. This channel appears to modulate the
release of excitatory neurotransmitters that participate in
epileptogenesis and pain sensation. Hence, gabapentin has
been used for the treatment of neuropathic pain. However,
its role in uremic pruritus is not well established. In a
randomized controlled crossover trial, Gunal et al.4
evaluated the effect of gabapentin (300 mg given thrice
weekly after dialysis) versus placebo in treating 25
hemodialysis patients for pruritus. Gabapentin lowered
the mean pruritus score (from 8.4 to 1.2 for gabapentin
versus 8.4 to 7.6 with placebo-treated patients). However,
this study had several limitations, including a small
sample size, limited information on demographics of the
study population, subjective evaluation of itching, only
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once-daily assessment of itching, the use of a high dose of
gabapentin, and the absence of between-group compari-
sons. In a more recent trial, Naini et al.5 studied 34 patients
in a randomized placebo-controlled trial and using a
high dose of gabapentin (400 mg thrice weekly post
dialysis) reported efficacy for gabapentin over placebo.
This study also had several limitations. Further, as
Manenti and Vaglio have previously pointed out,6 the high
dose of gabapentin used in these trials could lead to
sedation and neurotoxicity in dialysis patients. They
advocate a modest initial starting dose of gabapentin
(that is, 100 mg given thrice weekly after dialysis) and
careful nursing surveillance when administering gabapen-
tin. This lower dose, as far as we are aware, has only been
tested in a pilot (nonrandomized controlled) study.7 Thus,
while we agree that gabapentin could represent a potential
therapeutic option, in our own practice, we do not
currently use this agent for the treatment of uremic
pruritus.
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